Message Font: Serif | Sans-Serif
No. of Recommendations: 0

Boston Scientific (BSX ): Reiterates 5 STARS (buy)
Analyst: Robert Gold

The company posted fourth quarter results in line with recent guidance, with sales up 19% before an $11 million currency benefit, and operating earnings per share of 31 cents vs. 20 cents. Boston Scientific notes that January results met their plan, with some upside in urology. The European launch of its drug-coated stent is expected by mid-February. S&P still anticipates a premarketing approval (PMA) filing in the U.S. in June, with the release of Taxus IV data in September and a launch in the early fourth quarter. S&P continues to see 2003 earnings per share at $1.30, and 2004 at $2.50. Estimated S&P Core earnings per share of 89 cents in 2002 is seen rising by 31% to $1.17 in 2003.
Print the post  


When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.